van Loon Welmoed, Schallenberg Emma, Mande Emmanuel, Musinguzi Patrick, Ngobi Paul, Atukunda Sharon, Rubaihayo John, Mockenhaupt Frank P
Institute of International Health, Charité Center for Global Health, Charité-Universitaetsmedizin Berlin, Berlin, Germany.
Infectious Diseases Institute, College of Health Sciences, Makerere University, Kampala, Central Region, Uganda.
Antimicrob Agents Chemother. 2025 Jun 4;69(6):e0175524. doi: 10.1128/aac.01755-24. Epub 2025 Apr 23.
In Fort Portal, Uganda, artemisinin resistance-associated mutations in ( = 126) were present in 4.8% (675V, 561H, and 441L). A mutation of unknown relevance, 490T, occurred in 9.5%. variants suggested increased lumefantrine tolerance (N86, 100%). Mutation 500N was absent, and 199S occurred in 12.8%. The latter is of unknown relevance. These data indicate an incipient emergence of artemisinin resistance in a crucial location between Rwandan and Ugandan resistance hotspots and hardly affected DR Congo.
在乌干达福特波特，126例样本中与青蒿素耐药相关的突变（675V、561H和441L）占4.8%。一种相关性未知的突变490T出现率为9.5%。某些变异提示对本芴醇耐受性增加（N86，100%）。不存在500N突变，199S突变出现率为12.8%，后者相关性未知。这些数据表明在卢旺达和乌干达耐药热点之间的关键位置已初现青蒿素耐药情况，且对刚果民主共和国影响极小。
